#hemophilia #clinicaltrials
A global study involving McMaster University researchers has trialled a potential new treatment that could be a game-changer for people living with hemophilia A, a life-threatening genetic blood disorder. Co-principal investigator Davide Matino said that once-weekly injections of efanesoctocog alfa can prevent bleeding and promote near-normal activity by the clotting agent factor VIII, crucial for stopping the prolonged bleeding caused by hemophilia A. People who took efanesoctocog alfa also enjoyed improved joint function, better overall health and less pain.
“With only one injection for an entire week, people with hemophilia A will enjoy normal or near-normal levels of factor VIII, which is unheard of. Previously, patients had to inject every other day, which was a huge burden for them, yet obtaining a lower level of protection” said Matino.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
LinkedIn: [ Ссылка ]
Website: [ Ссылка ]
Ещё видео!